Publications by authors named "H von Baum"

Background: Prehospital triage and treatment of patients with acute coma is challenging for rescue services, as the underlying pathological conditions are highly heterogenous. Recently, glial fibrillary acidic protein (GFAP) has been identified as a biomarker of intracranial hemorrhage. The aim of this prospective study was to test whether prehospital GFAP measurements on a point-of-care device have the potential to rapidly differentiate intracranial hemorrhage from other causes of acute coma.

View Article and Find Full Text PDF
Article Synopsis
  • The ComFluCOV trial enrolled 679 participants to test the safety and immune response of receiving an influenza vaccine alongside a COVID-19 vaccine.
  • Results showed that getting the flu shot did not negatively impact immune responses to either the Pfizer or AstraZeneca COVID-19 vaccines, as measured in saliva.
  • However, mucosal IgA antibodies were not present in response to the COVID-19 vaccines, highlighting the need for improved vaccines that can better prevent transmission or provide stronger immunity.
View Article and Find Full Text PDF

Background: Measurement of cardiac troponin (cTn) by a high sensitivity method is now the recommended strategy for the detection of myocardial injury. An international survey was undertaken to assess how this has been implemented.

Methods: A questionnaire based around 14 domains on cardiac biomarkers was distributed electronically with the aid of professional societies accessed by a web link within the invitation.

View Article and Find Full Text PDF

Natriuretic peptides (NP) play an essential role in heart failure (HF) regulation, and their measurement has improved diagnostic and prognostic accuracy. Clinical symptoms and objective measurements, such as NP levels, should be included in the HF definition to render it more reliable and consistent among observers, hospitals, and healthcare systems. BNP and NT-proBNP are reasonable surrogates for cardiac disease, and their measurement is critical to early diagnosis and risk stratification of HF patients.

View Article and Find Full Text PDF

In the last 20 years, the number of approved agents and agent classes for management of type 2 diabetes has expanded significantly. This more robust armamentarium affords us the opportunity to utilize drugs with complementary modes of action to address progressive hyperglycemia as insulin secretion declines over time. Furthermore, some of these agents provide additional benefits, such as weight loss, prevention of major adverse cardiac events (MACE), and protection against declining renal function.

View Article and Find Full Text PDF